AUSTIN, TX — August 18, 2025 — Leads & Copy — Form Bio, a provider of AI-powered solutions for genetic medicine and genome engineering, has appointed Michelle Chen, Ph.D., as President, Chief Executive Officer and member of the Board of Directors. Chen succeeds Form Bio’s co-founders Andrew Busey, CEO, and Kent Wakeford, President and COO.
Busey and Wakeford will remain engaged as strategic advisors and executive chair members of the board. Chen previously served as Chief Business Officer at Insilico Medicine and held senior leadership roles including SVP of Corporate Development at WuXi Biologics.
Since its launch, Form Bio has become a trusted innovation partner to gene therapy companies. The company delivers advanced AI/ML models, computational tools, and in silico solutions that accelerate development timelines, reduce risk, and optimize therapeutic design for manufacturability.
Angela Anderson, Form Bio, angela@formbio.com
Source: Form Bio
